Factor IX Polyklonale Antilichaam, FITC-vervoeging

Hemostasis following tissue injury involves the deployment of essential plasma procoagulants (prothrombin, and factors X, IX, V, and VIII), which are involved in a blood coagulation cascade that leads to the formation of insoluble fibrin clots and the promotion of platelet aggregation (1-3) . Coagulation factor IX (plasma thromboplastic component, F9, F.IX, HEMB) is a vitamin K-dependent, single chain serine protease that is synthesized in the liver and circulates as an inactive precursor (3,4) . Factor XIa mediated proteolytic cleavage of factor IX generates factor IXa, an active serine protease composed of a 145 amino acid light chain and a 236 amino acid catalytic heavy chain, linked through disulfide bonds (5) . Genetic alterations at the Factor IX locus such as point mutations, insertions and deletions, can lead to hemophilia B, also known as Christmas disease (6) .

Christmas Disease; Christmas factor; Coagulant factor IX; Coagulation factor 9; Coagulation factor IX plasma thromboplastic component; Coagulation factor IX; Coagulation factor IXa heavy chain; F9; FA9_HUMAN; Factor 9; Factor IX Deficiency; Factor9; FactorIX; FIX; GLA domain; Haemophilia B; MGC129641; MGC129642; P19 antibody Plasma thromboplastic component; Plasma thromboplastin component; PTC; Truncated coagulation factor IX.

2158

Human, Mouse, Rat

381-461/461

Factor IX

FITC

KLH conjugated synthetic peptide derived from human Coagulation factor IXa heavy chain

WB, IF

Purified by Protein A.

494nm/518nm

1µg/µl

WB (1:300-5000), IF ()

Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Unmodified

Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

2158